8.96

2.17% 0.19

After Hours: 8.85 -0.11 -1.23%

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $8.96, with a volume of 842.18K. It is up +2.17% in the last 24 hours and down -4.17% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Previous Close:

$8.77

Open:

$8.79

24h Volume:

842.18K

Relative Volume:

0.34

Market Cap:

$469.52M

Revenue:

$1.02B

Net Income/Loss:

$-757.20M

P/E Ratio:

-0.7417

EPS:

-12.08

Net Cash Flow:

$-257.90M

1W Performance:

-3.97%

1M Performance:

-4.17%

6M Performance:

+130.33%

1Y Performance:

+270.25%

1-Day Range:

$8.68

$9.05

1-Week Range:

$8.66

$9.892

52-Week Range:

$1.42

$15.10

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1181)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

240-631-3200

Address

400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD

Employee

1,600

Twitter

@emergentbiosolu

Next Earnings Date

2024-11-06

Latest SEC Filings

EBS's Discussions on Twitter

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Nov 04, 2024

Biotech Co. Emergent Gives Interim GC Permanent Role - Law360

Nov 04, 2024

Emergent BioSolutions appoints new chief medical officer - Investing.com

Nov 04, 2024

Oct 30, 2024

Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024

Oct 29, 2024

Emergent Bio's smallpox vaccine gets US approval for mpox - AOL

Oct 29, 2024

Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St

Oct 28, 2024

Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance

Oct 28, 2024

Oct 25, 2024

5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance

Oct 25, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.

Oct 25, 2024

Oct 23, 2024

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times

Oct 23, 2024

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian

Oct 23, 2024

Oct 21, 2024

Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat

Oct 21, 2024

Oct 15, 2024

Biopharma Layoffs Roundup - Contract Pharma

Oct 15, 2024

Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata - Yahoo Finance

Oct 15, 2024

Oct 14, 2024

3 Stocks Poised for Better Returns With New Analyst Coverage - Yahoo Finance

Oct 14, 2024

Oct 12, 2024

Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 84.1% in September - MarketBeat

Oct 12, 2024

Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 12, 2024

Oct 11, 2024